Trial Profile
A Phase I, Dose Escalation Study to Assess the Safety & Biological Activity of Interleukin 18 (SB-485232) Administered by IV Infusion in Combination With Pegylated Liposomal Doxorubicin (Doxil) in Advanced Stage Epithelial Ovarian Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Sep 2023
Price :
$35
*
At a glance
- Drugs Iboctadekin (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker
- Sponsors GSK
- 25 Mar 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
- 25 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Feb 2011 Planned end date changed from 1 Dec 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.